» Articles » PMID: 12676790

Immune Thrombocytopenic Purpura (ITP) Plasma and Purified ITP Monoclonal Autoantibodies Inhibit Megakaryocytopoiesis in Vitro

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2003 Apr 5
PMID 12676790
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

To determine if megakaryocytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are platelets, we have studied the effects of ITP plasma on in vitro megakaryocytopoiesis. Umbilical cord blood mononuclear cells were incubated in the presence of thrombopoietin and 10% plasma from either ITP patients (n = 53) or healthy donors. The yield of megakaryocytic cells, as determined by flow cytometry, was significantly reduced in the presence of ITP plasma containing antiplatelet glycoprotein Ib (GPIb) autoantibodies (P <.001) as compared with both the control and patient plasma with no detectable anti-GPIIb/IIIa or anti-GPIb autoantibodies. Platelet absorption of anti-GPIb autoantibodies in ITP plasmas resulted in double the megakaryocyte production of the same plasmas without absorption, whereas platelet absorption of control plasma had no effect on megakaryocyte yield. Furthermore, 2 human monoclonal autoantibodies isolated from ITP patients, 2E7, specific for human platelet glycoprotein IIb heavy chain, and 5E5, specific for a neoantigen on glycoprotein IIIa expressed on activated platelets, had significant inhibitory effects on in vitro megakaryocytopoiesis (P <.001). Taken together, these data indicate that autoantibodies against either platelet GPIb or platelet GPIIb/IIIa in ITP plasma not only are involved in platelet destruction, but may also contribute to the inhibition of platelet production.

Citing Articles

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia.

Evangelidis P, Tragiannidis K, Gavriilaki E, Tragiannidis A Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852180 PMC: 11763769. DOI: 10.3390/cimb47010065.


The Importance of Treating Subclinical Hypothyroidism in Patients With Immune Thrombocytopenia: A Case Report.

Manuja N, Daiya V, Malali S, Kadu A, Kumar S, Acharya S Cureus. 2024; 16(5):e59813.

PMID: 38846217 PMC: 11154087. DOI: 10.7759/cureus.59813.


Pathophysiology, Clinical Manifestations and Diagnosis of Immune Thrombocytopenia: Contextualization from a Historical Perspective.

Martinez-Carballeira D, Bernardo A, Caro A, Soto I, Gutierrez L Hematol Rep. 2024; 16(2):204-219.

PMID: 38651450 PMC: 11036214. DOI: 10.3390/hematolrep16020021.


Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia: A randomized clinical trial.

Zhu X, Zhao L, Riva N, Yu Z, Jiang M, Zhou F iScience. 2024; 27(5):109664.

PMID: 38646173 PMC: 11031822. DOI: 10.1016/j.isci.2024.109664.


Immune attack on megakaryocytes in immune thrombocytopenia.

Petito E, Gresele P Res Pract Thromb Haemost. 2024; 8(1):102345.

PMID: 38525349 PMC: 10960061. DOI: 10.1016/j.rpth.2024.102345.